Disposition (Details) - Biodefense Business [Member] |
Nov. 04, 2015
USD ($)
shares
|
|---|---|
| Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items] | |
| Sales of business, number of common stock shares eligible to receive | shares | 23,008 |
| Royalties receivable percentage on net sales | 15.00% |
| Maximum [Member] | |
| Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items] | |
| Cash payments from Nanotherapeutics | $ | $ 4,500,000 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The amount of contingent payments the company is entitled to receive related to sole performance of counterparty under the agreement. No definition available.
|
| X | ||||||||||
- Definition Royalty receivable percentage on net sales. No definition available.
|
| X | ||||||||||
- Definition Sales of business number of common stock shares eligible to receive. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|